Report Compares Regeneron Pharmaceuticals and Wave Life Sciences Financial Profiles
What happened
A published report compares Regeneron Pharmaceuticals and Wave Life Sciences across several business metrics, including risk, earnings, valuation, and institutional ownership. The comparison found that Regeneron Pharmaceuticals has higher gross revenue and earnings per share than Wave Life Sciences. Regarding risk, Regeneron Pharmaceuticals has a beta of 0.2, while Wave Life Sciences has a beta of -1.3. The report also noted that Wave Life Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals.
From tickerreport.com
Why it matters
The comparison details differences in operational profiles, such as net margins and return on equity, for both companies. Institutional investors hold 83.3% of Regeneron Pharmaceuticals shares, compared to 89.7% of Wave Life Sciences. Insider ownership is 7.0% for Regeneron Pharmaceuticals and 24.3% for Wave Life Sciences.
From tickerreport.com
Who's involved
- Regeneron PharmaceuticalsHealthcare company whose profile is compared to Wave Life Sciences.
- Wave Life SciencesBiotechnology company whose profile is compared to Regeneron Pharmaceuticals.
Keep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
Nothing else this week.
-
Wave Life Sciences
biotechnology company
Nothing else this week.